-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Loss-making Tango Therapeutics (NASDAQ:TNGX) Sheds a Further US$64m, Taking Total Shareholder Losses to 18% Over 1 Year
Loss-making Tango Therapeutics (NASDAQ:TNGX) Sheds a Further US$64m, Taking Total Shareholder Losses to 18% Over 1 Year
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That downside risk was realized by Tango Therapeutics, Inc. (NASDAQ:TNGX) shareholders over the last year, as the share price declined 18%. That's disappointing when you consider the market declined 7.7%. Because Tango Therapeutics hasn't been listed for many years, the market is still learning about how the business performs. In the last ninety days we've seen the share price slide 20%.
If the past week is anything to go by, investor sentiment for Tango Therapeutics isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
Check out our latest analysis for Tango Therapeutics
Tango Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
In just one year Tango Therapeutics saw its revenue fall by 40%. That's not what investors generally want to see. Shareholders have seen the share price drop 18% in that time. That seems pretty reasonable given the lack of both profits and revenue growth. We think most holders must believe revenue growth will improve, or else costs will decline.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
We doubt Tango Therapeutics shareholders are happy with the loss of 18% over twelve months. That falls short of the market, which lost 7.7%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. It's worth noting that the last three months did the real damage, with a 20% decline. This probably signals that the business has recently disappointed shareholders - it will take time to win them back. It's always interesting to track share price performance over the longer term. But to understand Tango Therapeutics better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Tango Therapeutics (including 1 which is potentially serious) .
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
从上涨的市场中获益的最简单方式是购买指数基金。积极投资者的目标是买入表现远远好于大盘的股票--但在这个过程中,他们面临表现不佳的风险。这种下行风险通过以下方式实现探戈治疗公司新浪纳斯达克(Sequoia Capital:TNGX)去年股价下跌18%,导致其股价下跌。当你考虑到市场下跌了7.7%时,这是令人失望的。由于Tango治疗公司已经多年没有上市了,市场仍在了解该业务的表现。在过去的90天里,我们看到股价下跌了20%。
如果以过去一周为标准,投资者对Tango Treeutics的情绪并不积极,所以让我们看看基本面和股价之间是否存在错配。
查看我们对Tango Treateutics的最新分析
探戈治疗公司目前还没有盈利,所以大多数分析师都会关注收入增长,以了解基本业务的增长速度。当一家公司没有盈利时,我们通常预计会看到良好的收入增长。这是因为,如果一家公司的收入增长微不足道,而且永远不会盈利,那么很难相信它会持续下去。
在短短一年的时间里,Tango治疗公司的收入下降了40%。这并不是投资者通常希望看到的。在此期间,股东们看到该公司股价下跌了18%。考虑到利润和收入都没有增长,这似乎相当合理。我们认为,大多数持有者肯定相信,收入增长将会改善,否则成本将会下降。
该公司的收入和收益(随着时间的推移)如下图所示(点击查看具体数字)。
资产负债表的强健至关重要。也许很值得一看我们的免费报告其财务状况如何随着时间的推移而发生变化。
不同的视角
我们怀疑Tango Treeutics的股东对过去12个月亏损18%的情况感到满意。这一数字低于大盘,大盘下跌7.7%。这令人失望,但值得记住的是,整个市场的抛售不会有任何帮助。值得注意的是,过去三个月造成了真正的损失,下降了20%。这可能表明,该公司最近让股东们失望了--要赢回他们还需要时间。跟踪股价的长期表现总是很有趣的。但为了更好地理解Tango治疗,我们需要考虑许多其他因素。为此,您应该了解2个警告标志我们已经发现了Tango治疗公司(包括1家可能很严重的公司)。
如果你像我一样,你会的不想怀念这一切吗?免费内部人士正在收购的成长型公司名单。
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧